REGISTER RECORD · clinicaltrials.gov
NCT00908180
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | UNKNOWN: last verified some time ago; the register no longer confirms its status |
|---|---|
| Register last updated | 2013-08-02 |
| Retrieved by this site | 2026-08-31 |
| Source | https://clinicaltrials.gov/study/NCT00908180 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.